Vaccines,
Год журнала:
2021,
Номер
9(6), С. 679 - 679
Опубликована: Июнь 21, 2021
This
review
describes
investigations
of
specific
topics
that
lie
within
the
general
subject
HSV1’s
role
in
AD/dementia,
published
last
couple
years.
They
include
studies
on
following:
relationship
HSV1
to
AD
using
neural
stem
cells;
apparent
protective
effects
treatment
infection
or
VZV
with
antivirals
prior
onset
dementia;
putative
involvement
AD/dementia;
possible
human
herpes
virus
6
(HHV6)
AD;
seemingly
reduced
risk
dementia
after
vaccination
diverse
types
vaccine,
and
association
shown
some
vaccine
frequency
reactivation;
anti-HSV
serum
antibodies
supporting
linkage
brain
APOE-ε4
carriers,
between
APOE
cognition,
AD/dementia.
The
conclusions
are
there
is
now
overwhelming
evidence
for
role—probably
causal—in
AD,
when
it
present
further
should
be
made
prevention
disease
by
vaccination,
prolonged
antiviral
before
onset.
Signal Transduction and Targeted Therapy,
Год журнала:
2023,
Номер
8(1)
Опубликована: Июль 5, 2023
Abstract
Transient
receptor
potential
(TRP)
channels
are
sensors
for
a
variety
of
cellular
and
environmental
signals.
Mammals
express
total
28
different
TRP
channel
proteins,
which
can
be
divided
into
seven
subfamilies
based
on
amino
acid
sequence
homology:
TRPA
(Ankyrin),
TRPC
(Canonical),
TRPM
(Melastatin),
TRPML
(Mucolipin),
TRPN
(NO-mechano-potential,
NOMP),
TRPP
(Polycystin),
TRPV
(Vanilloid).
They
class
ion
found
in
numerous
tissues
cell
types
permeable
to
wide
range
cations
such
as
Ca
2+
,
Mg
Na
+
K
others.
responsible
various
sensory
responses
including
heat,
cold,
pain,
stress,
vision
taste
activated
by
number
stimuli.
Their
predominantly
location
the
surface,
their
interaction
with
physiological
signaling
pathways,
unique
crystal
structure
make
TRPs
attractive
drug
targets
implicate
them
treatment
diseases.
Here,
we
review
history
discovery,
summarize
structures
functions
family,
highlight
current
understanding
role
pathogenesis
human
disease.
Most
importantly,
describe
channel-related
therapeutic
interventions
diseases
limitations
targeting
clinical
applications.
Frontiers in Neuroscience,
Год журнала:
2021,
Номер
14
Опубликована: Янв. 8, 2021
Aging
is
the
time-dependent
process
that
all
living
organisms
go
through
characterized
by
declining
physiological
function
due
to
alterations
in
metabolic
and
molecular
pathways.
Many
decades
of
research
have
been
devoted
uncovering
cellular
changes
progression
aging
revealed
not
with
same
chronological
age
exhibit
age-related
declines
function.
In
assessing
biological
age,
factors
such
as
epigenetic
changes,
telomere
length,
oxidative
damage,
mitochondrial
dysfunction
rescue
mechanisms
autophagy
play
major
roles.
Recent
studies
focused
on
aging,
particularly
mitophagy
its
role
energy
generation
reactive
species
mitochondria.
Mitophagy
has
implicated
playing
a
pathogenesis
many
diseases,
including
Alzheimer’s
disease
(AD),
Parkinson’s,
Huntington’s,
amyotrophic
lateral
sclerosis.
The
purpose
our
article
highlight
how
defects
these
pathways
contribute
markers
AD.
This
also
discusses
dysfunction,
abnormal
dynamics,
impaired
biogenesis,
defective
are
related
AD
progression.
highlights
recent
amyloid
beta
phosphorylated
tau
relation
Biomedicine & Pharmacotherapy,
Год журнала:
2022,
Номер
148, С. 112681 - 112681
Опубликована: Фев. 14, 2022
Alzheimer's
disease
(AD)
is
the
most
common
neurodegenerative
disease,
with
cognitive
decline
as
primary
clinical
feature.
According
to
epidemiological
statistics,
50
million
people
worldwide
are
currently
affected
by
disease.
Although
new
drugs
such
aducanumab
have
been
approved
for
use
in
treatment
of
AD,
none
them
reversed
progression
AD.
MicroRNAs
(miRNAs)
small
molecule
RNAs
that
exert
their
biological
functions
regulating
expression
intracellular
proteins,
and
differential
abundance
varieties
found
between
central
peripheral
tissues
AD
patients
healthy
controls.
This
article
will
summarise
changes
miRNAs
process,
potential
role
diagnostic
markers
therapeutic
targets
be
explored.
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Авг. 23, 2024
Abstract
Alzheimer’s
disease
(AD)
stands
as
the
predominant
form
of
dementia,
presenting
significant
and
escalating
global
challenges.
Its
etiology
is
intricate
diverse,
stemming
from
a
combination
factors
such
aging,
genetics,
environment.
Our
current
understanding
AD
pathologies
involves
various
hypotheses,
cholinergic,
amyloid,
tau
protein,
inflammatory,
oxidative
stress,
metal
ion,
glutamate
excitotoxicity,
microbiota-gut-brain
axis,
abnormal
autophagy.
Nonetheless,
unraveling
interplay
among
these
pathological
aspects
pinpointing
primary
initiators
require
further
elucidation
validation.
In
past
decades,
most
clinical
drugs
have
been
discontinued
due
to
limited
effectiveness
or
adverse
effects.
Presently,
available
primarily
offer
symptomatic
relief
often
accompanied
by
undesirable
side
However,
recent
approvals
aducanumab
(
1
)
lecanemab
2
Food
Drug
Administration
(FDA)
present
potential
in
disrease-modifying
Nevertheless,
long-term
efficacy
safety
need
Consequently,
quest
for
safer
more
effective
persists
formidable
pressing
task.
This
review
discusses
pathogenesis,
advances
diagnostic
biomarkers,
latest
updates
trials,
emerging
technologies
drug
development.
We
highlight
progress
discovery
selective
inhibitors,
dual-target
allosteric
modulators,
covalent
proteolysis-targeting
chimeras
(PROTACs),
protein-protein
interaction
(PPI)
modulators.
goal
provide
insights
into
prospective
development
application
novel
drugs.
